Back
Saturday, 21 Aug, 2021
Covid-19 vaccine by Arcturus and Singapore's Duke-NUS in phase 2 trials
Three different Covid-19 messenger RNA vaccines which may have reduced side effects when administered are being developed with Singapore's involvement in their clinical trials. The first vaccine, known as ARCT-021, targets the wildtype, or original Sars-CoV-2 virus, and was developed together with the Duke-NUS Medical School in Singapore. Local phase two trials, administered by SingHealth's Investigational Medicine Unit, are still ongoing.
Original article: Covid-19 vaccine by Arcturus and Singapore's Duke-NUS in phase 2 trials